Treatment of lymphatic malformations in children: 10 years of experience
DOI:
https://doi.org/10.15574/PS.2022.75.5Keywords:
lymphatic malformations, children, sclerotherapy, target therapyAbstract
Purpose is to identify the factors that determine the clinical features of the LMs, their complications and the choice of treatment options.
Materials and methods. 225 children with LMs who underwent treatment since 2011 to 2020 were enrolled. They were grouped according to ISSVA 2018 classification. Clinical presentation, treatment options, complications and outcomes were analyzed. One-variant analysis using Pearson’s χ2 test was used to evaluate qualitative data.
Results. 214 (95.1%) patients had cystic LMs, 11 (4.9%) had combined LMs. 129 (57.3%) LMs were cervicofacial, 17 (11.9%) patients developed airways compression and 6 (4.2%) required tracheostomy. 8 (3.6%) patients developed 10 lymphatic leaks episodes, 3 were lethal. 112 (86.8%) patients with cervicofacial, 5 (11.6%) abdominal, 10 (84.6%) axillar, and 12 (92.2%) extremities LMs underwent sclerotherapy. Surgical resections prevailed in abdominal LMs, 32 (74.5%), versus 4 (3.1%) cervicofacial LMs. 10 (4.4%) patients with combined and complicated cystic LMs underwent systemic sirolimus therapy. Results of treatment were excellent in 116 (51.6%) patients, good in 82 (36.4%), satisfactory in 23 (10.2%), and unsatisfactory in 4 (1.8%), with 4 mortalities caused by sepsis (n=1) and by massive lymph leakage (n=3).
Conclusions. The most life-threatening LMs complications are airways compression and uncontrollable lymphatic leakages. Several approaches were used, including surgery, sclerotherapy, and target therapy. Surgery is optional for abdominal LMs but potentially harmful in cervicofacial. Treatment of combined LM is continuous and requires a combination of different methods.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of all participating institutions. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
References
Adams DM, Trenor CC, Hammill FM, Vinks AA, Patel MN, Chaudry G et al. (2016). Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. J Pediatr. 137 (2): e20153257. https://doi.org/10.1542/peds.2015-3257; PMid:26783326 PMCid:PMC4732362
Chaudry G. (2019). Complex Lymphatic Anomalies and Therapeutic Options. Tech Vasc Interv Radiol. 22 (4): 100632. https://doi.org/10.1016/j.tvir.2019.100632; PMid:31864531
Cronan J, Gill AE, Shah JH, Hawkins CM. (2020). The Role of Interventional Radiologists in the Treatment of Congenital Lymphatic Malformation. Semin Intervent Radiol. 37 (3): 285-294. https://doi.org/10.1055/s-0040-1713446; PMid:32773954 PMCid:PMC7394567
Croteau SE, Kozakewich HP, Perez-Atayde AR, Fishman SJ, Alomari AI, Chaudry G, Mulliken JB, Trenor CC. (2014). Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr. 164 (2): 383-388. https://doi.org/10.1016/j.jpeds.2013.10.013; PMid:24252784 PMCid:PMC3946828
Dubois J, Thomas-Chaussé F, Soulez G. (2019). Common (Cystic) Lymphatic Malformations: Current Knowledge and Management. Tech Vasc Interv Radiol. 22 (4): 100631. https://doi.org/10.1016/j.tvir.2019.100631; PMid:31864533
Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, Costa J, Ferreira J. (2020). Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review. J Vasc Surg. 71 (1): 318-327. https://doi.org/10.1016/j.jvs.2019.06.217; PMid:31676179
Ghaffarpour N, Petrini B, Svensson LA, Boman K, Wester T, Claesson G. (2015). Patients with lymphatic malformations who receive the immunostimulant OK-432 experience excellent long-term outcomes Acta Paediatr. 104 (11): 1169-1173. https://doi.org/10.1111/apa.13086; PMid:26081020
Goyal P, Alomari AI, Kozakewich HP, Trenor CC 3rd, Perez-Atayde AR, Fishman SJ, Greene AK, Shaikh R, Chaudry G. (2016). Imaging features of kaposiform lymphangiomatosis. Pediatr Radiol. 46 (9): 1282-1290. https://doi.org/10.1007/s00247-016-3611-1; PMid:27053281
Hammill AM, Wentzel MS, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. (2011). Sirolimus for the treatment of complicated vascular anomaliesin children. Pediatr Blood Cancer. 57: 1018-1024. https://doi.org/10.1002/pbc.23124; PMid:21445948
Horbach SE, Lokhorst MM, Saeed P, de Goüyon Matignon, de Pontouraude CM, Rothová A, van der Horst CM. (2016). Sclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents. J Plast Reconstr Aesthet Surg. 69 (3): 295-304. https://doi.org/10.1016/j.bjps.2015.10.045; PMid:26723834
Hortlund M, Arroyo Muhr LS, Storm S et al. (2017). Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer. 140 (5): 1091-1101. https://doi.org/10.1002/ijc.30531; PMid:27870055
Huk YuM, Zyma AM, Cheverda AL, Kincha-Polischuk TM et al. (2020). Necessity and feasibility of limb length discrepancy correction in congenital vascular malformations in children. Paediatric surgery. Ukraine. 2 (67): 68-72. doi 10.15574/PS.2020.67.68
Kulungowski AM, Patel M. (2020). Lymphatic malformations Semin Pediatr Surg. 29 (5): 150971. https://doi.org/10.1016/j.sempedsurg.2020.150971; PMid:33069296
Lala S, Mulliken JB, Alomari A, Fishman SJ, Kozakewich HP, Gulraiz Chaudry G. (2016). Gorham-Stout disease and generalized lymphatic anomaly-clinical, radiologic, and histologic differentiation Skeletal Radiol. 42 (7): 917-924. https://doi.org/10.1007/s00256-012-1565-4; PMid:23371338
Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovée JV et al. (2015). Lymphatic and other vascular malformative / overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 166: 1048-54.e1-5. https://doi.org/10.1016/j.jpeds.2014.12.069; PMid:25681199 PMCid:PMC4498659
Mäkinen T, Boon LM, Vikkula M, Alitalo K. (2021). Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies. Circ Res. 129 (1): 136-154. https://doi.org/10.1161/CIRCRESAHA.121.318142; PMid:34166072
Morgan P, Keller R, Patel K. (2016). Evidence-Based Management of Vascular Malformations. Facial Plast Surg. 32 (2): 162-176. https://doi.org/10.1055/s-0036-1581141; PMid:27097138
Nadal M, Giraudeau B, Tavernier E, Jonville-Bera AP et al. (2016). Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review. Acta Derm Venereol. 96 (4): 448-452. https://doi.org/10.2340/00015555-2300; PMid:26607948
Ozeki M, Fujino A, Matsuoka K, Nosaka S, Kuroda T, Fukao T. (2016). Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease. Pediatr Blood Cancer. 63 (5): 832-838. https://doi.org/10.1002/pbc.25914; PMid:26806875
Ozeki M, Fukao T. (2019). Generalized Lymphatic Anomaly and Gorham-Stout Disease: Overview and Recent Insights. Adv Wound Care (New Rochelle). 8 (6): 230-245. https://doi.org/10.1089/wound.2018.0850; PMid:31236308 PMCid:PMC6589502
Ricci KW, Hammill AM, Mobberley-Schuman P, Nelson SC, Glade Bender JLG et al. (2019). Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. Pediatr Blood Cancer. 66 (5): e27614. https://doi.org/10.1002/pbc.27614; PMid:30672136 PMCid:PMC6428616
Wiegand S, Wichmann G, Dietz A. (2018). Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review. Lymphat Res Biol. 16 (4): 330-339. https://doi.org/10.1089/lrb.2017.0062; PMid:29924669
WMADH. (2013). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 310 (20): 2191-2194. https://doi.org/10.1001/jama.2013.281053; PMid:24141714
Ying H, Qiao C, Yang X, Lin X. (2018). A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas. Pediatrics. 141 (5): S425-S429. https://doi.org/10.1542/peds.2016-2919; PMid:29610165
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Paediatric Surgery (Ukraine)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “PAEDIATRIC SURGERY. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license(СС BY-NC).
Authors transfer the copyright to the Journal “PAEDIATRIC SURGERY.UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
